

Impact and Value of Biomarker Testing

Scott M. Lippman, MD
Distinguished Professor of Medicine
Associate Vice Chancellor for Cancer Research and Care

Impact of Biomarker Testing in Oncology

Making precision medicine relevant
for every cancer patient

Precision Cancer Medicine

Makes a profound impact on patient survival

- ▶ Genomic Testing*
- ▶ Matching drugs targeting actionable genomic alterations


*single most important factor in treating patients
genomic testing 'gap' revealed in ~38,000 patient study
(Schilsky *NEJM* 12/2022) larger in underserved
communities

Precision Cancer Medicine

Makes a profound impact on patient survival

- ▶ Genomic Testing
- ▶ Matching drugs targeting actionable genomic alterations

Lung Cancer 2.2M / year



A woman with dark hair, wearing a teal shirt, is shown in profile from the chest up. She is looking towards the right with a thoughtful expression. The background is dark, and the lighting highlights her face and the texture of her shirt.


Only 20% of cancer patients in the U.S.

Receive FDA-approved companion diagnostics

Biomarker Legislation will change that.

Nivolumab is approved by the FDA & all worldwide agencies for ALL recurrent HNSC

Less than 20% of Head and Neck Cancer Patients Benefit from Immunotherapy



Thank you.

